Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 2/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461389 | 0.85 | KDM1A (0.48) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 | |
| SCHEMBL7456585 | 0.85 | KDM1A (0.48) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 | |
| SCHEMBL7470528 | 0.85 | KDM1A (0.48) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 | |
| SCHEMBL7465250 | 0.84 | F2 (0.40) | — | |
| SCHEMBL7459201 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 | |
| SCHEMBL7460130 | 0.78 | KDM1A (0.50) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 | |
| SCHEMBL7525265 | 0.76 | KDM1A (0.52) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 | |
| SCHEMBL7466377 | 0.73 | KDM1A (0.47) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 | |
| SCHEMBL7458922 | 0.73 | KDM1A (0.53) | SLC6A2SLC6A4KDM1AKCNH2RCOR1 | |
| Hydrochloric Acid SCHEMBL7462249 | 0.70 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KDM1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | SLC6A2 105/4885SLC6A4 134/4885SLC6A3 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.